Limited trials of TNFα inhibitors in CGD patients have shown effectiveness in the treatment of arthritis (56), bowel fistulas (57) and reducing the symptoms of interstitial bowel disease, a frequent inflammatory complication in this population (5). The gene discussed is TNF; the disease is chronic granulomatous disease.